CR8954A - Politerapia empleando proteinas de fusion de transferrina que incluyen a glp-1 - Google Patents

Politerapia empleando proteinas de fusion de transferrina que incluyen a glp-1

Info

Publication number
CR8954A
CR8954A CR8954A CR8954A CR8954A CR 8954 A CR8954 A CR 8954A CR 8954 A CR8954 A CR 8954A CR 8954 A CR8954 A CR 8954A CR 8954 A CR8954 A CR 8954A
Authority
CR
Costa Rica
Prior art keywords
fusion proteins
transferrine
polytherapy
proteins including
including glp
Prior art date
Application number
CR8954A
Other languages
English (en)
Inventor
Sadeghi Homayoun
Prior Christopher
J Balance David
Original Assignee
Biorexis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorexis Pharmaceutical Corp filed Critical Biorexis Pharmaceutical Corp
Publication of CR8954A publication Critical patent/CR8954A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)

Abstract

La presente invencion suministra proteinas de fusion de transferina que incluyen peptidos terapeuticos o proteinas de uso terapeutico que son suceptibles a la ruptura con proteasa. La presente invencion suministra tambien proteinas de fusion de transferrina que incluyen peptidos o protinas de uso terapeutico que son sensibles, resistentes o parcialmente resistentes a la ruptura con proteasas.
CR8954A 2004-08-03 2007-03-02 Politerapia empleando proteinas de fusion de transferrina que incluyen a glp-1 CR8954A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59803104P 2004-08-03 2004-08-03

Publications (1)

Publication Number Publication Date
CR8954A true CR8954A (es) 2007-10-02

Family

ID=35839920

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8954A CR8954A (es) 2004-08-03 2007-03-02 Politerapia empleando proteinas de fusion de transferrina que incluyen a glp-1

Country Status (19)

Country Link
EP (1) EP1814599A4 (es)
JP (1) JP2008509153A (es)
KR (1) KR20070085224A (es)
CN (1) CN101035568A (es)
AP (1) AP2007003920A0 (es)
AU (1) AU2005271403A1 (es)
BR (1) BRPI0514115A (es)
CA (1) CA2575756A1 (es)
CR (1) CR8954A (es)
EA (1) EA200700391A1 (es)
GB (1) GB2431583A (es)
IL (1) IL181108A0 (es)
MA (1) MA28843B1 (es)
MX (1) MX2007001424A (es)
NO (1) NO20071018L (es)
RU (1) RU2007107808A (es)
TN (1) TNSN07039A1 (es)
WO (1) WO2006017688A2 (es)
ZA (1) ZA200701484B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
WO2006096515A2 (en) * 2005-03-04 2006-09-14 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
IN2015DN00888A (es) 2006-02-22 2015-07-10 Mannkind Corp
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
CN101511868B (zh) * 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
WO2008033395A2 (en) * 2006-09-14 2008-03-20 Biorexis Pharmaceutical Corporation Melanocortin and transferrin fusion proteins
US8598314B2 (en) 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101628410B1 (ko) 2008-06-20 2016-06-08 맨카인드 코포레이션 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CN104721825B (zh) 2009-06-12 2019-04-12 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
EP2610619B1 (en) * 2010-08-27 2020-01-08 University of Miyazaki Hemokinin-1 receptor and hemokinin-1-derived peptide
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
RU2477726C1 (ru) * 2011-10-18 2013-03-20 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Замещенные феноксиуксусные кислоты, их эфиры и амиды, включающие 2,6-диоксо-2,3,6,7-тетрагидро-1н-пурин-8-иловый фрагмент, - антагонисты аденозинового a2a рецептора и их применение
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
CN103160565A (zh) * 2011-12-09 2013-06-19 彩虹天健康科技研究(北京)有限责任公司 Unc-51激酶影响细胞运铁蛋白的胞吞作用
CA2871468C (en) 2012-04-23 2021-09-21 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
CN103275177B (zh) * 2013-06-24 2015-08-12 南京财经大学 具有肾素和ace双重抑制活性的小肽、其制备方法及应用
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
FR3027395B1 (fr) * 2014-10-17 2016-10-21 Biomerieux Sa Composition pour dosage immuno-enzymatique par immunofluorescence et ses utilisations
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
CN106397606B (zh) * 2015-01-28 2020-11-10 中国科学院天津工业生物技术研究所 一种多肽复合物作为sst药物载体的应用、方法及其融合蛋白复合物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2018079702A1 (ja) 2016-10-28 2018-05-03 株式会社Ｎｒｌファーマ ラクトフェリン／アルブミン融合タンパク質及びその製造方法
US11459368B2 (en) 2017-07-14 2022-10-04 Livactus, Inc. Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance
WO2019243502A1 (en) 2018-06-21 2019-12-26 Novo Nordisk A/S Novel compounds for treatment of obesity
CN110218259B (zh) * 2019-06-24 2022-09-16 王跃驹 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用
CN112661862B (zh) * 2020-12-25 2023-03-31 深圳大学 一种融合蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US7285526B2 (en) * 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
AU9063801A (en) * 2000-09-06 2002-03-22 Aventis Pharma Sa Methods and compositions for diseases associated with amyloidosis
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
WO2004019872A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Oral delivery of modified transferrin fusion proteins
AU2003201274A1 (en) * 2002-01-11 2003-07-24 Novo Nordisk A/S Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains

Also Published As

Publication number Publication date
RU2007107808A (ru) 2008-09-10
EA200700391A1 (ru) 2007-10-26
CA2575756A1 (en) 2006-02-16
CN101035568A (zh) 2007-09-12
GB2431583A (en) 2007-05-02
EP1814599A4 (en) 2008-12-17
JP2008509153A (ja) 2008-03-27
TNSN07039A1 (fr) 2008-06-02
WO2006017688A3 (en) 2006-08-03
NO20071018L (no) 2007-04-11
AP2007003920A0 (en) 2007-02-28
ZA200701484B (en) 2008-07-30
KR20070085224A (ko) 2007-08-27
AU2005271403A1 (en) 2006-02-16
MA28843B1 (fr) 2007-09-03
WO2006017688A2 (en) 2006-02-16
BRPI0514115A (pt) 2008-05-27
IL181108A0 (en) 2007-07-04
MX2007001424A (es) 2008-03-13
EP1814599A2 (en) 2007-08-08
GB0703685D0 (en) 2007-04-04

Similar Documents

Publication Publication Date Title
CR8954A (es) Politerapia empleando proteinas de fusion de transferrina que incluyen a glp-1
EA200700210A1 (ru) ВАРИАНТЫ ОБЛАСТИ Fc
EP1699920A4 (en) NEW RECOMBINANT PROTEINS WITH FREE N-TERMINAL THIOL
DE60121729D1 (de) Prion Proteindimere für Impfungen
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
LTC1641823I2 (lt) GLP-1 analogo sulieti baltymai
CR8444A (es) Immunogenic peptide carrier conjugates and methods of producing same
MX2007006830A (es) Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
ATE542920T1 (de) Modifiziertes menschliches wachstumshormon
DE60226724D1 (de) Antimikrobielles polypeptid
NO20061722L (no) Nye GLP-1 derivater
ATE513917T1 (de) Bakterielle expression von proteaseinhibitoren und varianten davon
HN2002000291A (es) Alquinos como inhibidores de metodo proteinasa matriz
BRPI0510674A (pt) variantes fc otimizadas
EE200300408A (et) Aktiivsete valkude saagise suurendamine
CR9637A (es) Proteinas de enlace il-6
ATE404225T1 (de) Radiofluorierte peptide
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
BR0306905A (pt) Vacinas de flavivìrus
ATE446314T1 (de) Methode zur reinigung von fsh
CR11059A (es) Novedosas moleculas de anticuerpos y acidos nucleicos que se enlazan con la proteina de tension fungica hsp90
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
DE50206480D1 (de) Antimikrobiell wirkendes peptid

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)